Renishaw PLC
LSE:RSW
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 145
3 725
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Renishaw PLC
Renishaw PLC began its journey in 1973, sparked by the innovative spirit of Sir David McMurtry and John Deer. Initially rooted in the creation of more precise measuring equipment, Renishaw has navigated technological mazes to become a global leader in measurement, healthcare, and manufacturing technologies. The spark that lit Renishaw’s torch was McMurtry's invention of the touch-trigger probe while working at Rolls-Royce, a defining moment that paved the way for the company’s focus on metrology: the science of measurement. Today, this niche expertise enables Renishaw to provide a multitude of industries—from aerospace to healthcare—with sophisticated solutions that enhance precision and efficiency across the globe.
Renishaw’s financial health flourishes through its diverse yet intricately connected product offerings. Core to its business model is metrology, where it sells advanced systems and products like coordinate measuring machines, machine tool probes, and software. These products are vital for manufacturing companies seeking to ensure higher quality control and production efficiencies. Beyond metrology, Renishaw dabbles in healthcare, particularly in dental and neurological fields, with its innovative 3D printing technologies and stereotactic neurosurgery tools that offer new vistas in patient care. The synergy between traditional precision measurement and cutting-edge innovation amplifies its market presence, thus securing Renishaw’s place in both established and emerging industries.
Renishaw PLC began its journey in 1973, sparked by the innovative spirit of Sir David McMurtry and John Deer. Initially rooted in the creation of more precise measuring equipment, Renishaw has navigated technological mazes to become a global leader in measurement, healthcare, and manufacturing technologies. The spark that lit Renishaw’s torch was McMurtry's invention of the touch-trigger probe while working at Rolls-Royce, a defining moment that paved the way for the company’s focus on metrology: the science of measurement. Today, this niche expertise enables Renishaw to provide a multitude of industries—from aerospace to healthcare—with sophisticated solutions that enhance precision and efficiency across the globe.
Renishaw’s financial health flourishes through its diverse yet intricately connected product offerings. Core to its business model is metrology, where it sells advanced systems and products like coordinate measuring machines, machine tool probes, and software. These products are vital for manufacturing companies seeking to ensure higher quality control and production efficiencies. Beyond metrology, Renishaw dabbles in healthcare, particularly in dental and neurological fields, with its innovative 3D printing technologies and stereotactic neurosurgery tools that offer new vistas in patient care. The synergy between traditional precision measurement and cutting-edge innovation amplifies its market presence, thus securing Renishaw’s place in both established and emerging industries.
Revenue Guidance: H2 2025 revenue is guided between £354M and £394M, implying -2% to +9% compared to the prior year, with management citing ongoing uncertainty as the reason for the wide range.
Order Intake: Order book has improved across regions, especially in semiconductor and consumer electronics, but visibility remains short and subject to rapid changes.
Margin Pressures: Pricing pressure in APAC and product mix are impacting gross margin, but productivity and automation investments are expected to support margins.
Cash & CapEx: Strong cash conversion and lower CapEx in H1 due to completion of property investments; management regularly reviews cash needs and is cautious about returning excess cash to shareholders.
Supply Chain Issues: A supply chain quality issue in Q2 led to £2M of nonrecurring costs and about £1M of revenue shift from H1 to H2, with controls now in place to prevent recurrence.
Emerging Businesses: Loss-making segments like medical devices are being reviewed for external investment; emerging businesses are not currently contributing to profitability but show growth potential.
Regional Demand: US market remains positive despite political uncertainty; China demand is steady but faces ongoing pricing pressure and competition.
Cost Actions: Focus remains on productivity, automation, and IT transformation to achieve a targeted 20% margin.
